Filing Flows › Aquestive Therapeutics (AQST) › Q2 2026 › vs Q1 2026
Aquestive Therapeutics (AQST) Q2 2026 vs Q1 2026 (quarter over quarter)
Aquestive Therapeutics's revenue fell $627K (-4%) from $14.4M in Q1 2026 to $13.8M in Q2 2026. The biggest changes: License and royalty revenue (a) −$4.1M (-75%); Manufacture and supply revenue +$3.1M (+35%); Co-development and research fees +$324K (+126%).
Aquestive Therapeutics, Q2 2026: revenue $13.8M (+38% year over year), operating margin -59.5%, net loss $22.9M, operating cash flow −$9.4M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Manufacture and supply revenue | $11.9M | $8.8M | $3.1M | +35% |
| License and royalty revenue (a) | $1.3M | $5.4M | −$4.1M | -75% |
| Co-development and research fees | $582K | $258K | $324K | +126% |
| Revenue | $13.8M | $14.4M | −$627K | -4% |
| Net loss | $22.9M | $8.1M | $14.8M | +184% |
| Costs & expenses | $36.7M | $22.5M | $14.2M | +63% |
| Operating costs | $22.0M | $18.6M | $3.4M | +18% |
| Interest & other, net | $14.6M | $3.9M | $10.8M | +280% |
| Cost of revenue | $4.0M | $3.5M | $548K | +16% |
| Research & development | $4.0M | $4.2M | −$242K | -6% |
| SG&A | $14.1M | $11.0M | $3.1M | +28% |
| Operating cash sources | $22.9M | $8.1M | $14.8M | +184% |
| Depreciation | $136K | $113K | $23K | +20% |
| Share-based compensation | $2.9M | $2.3M | $577K | +25% |
| Working capital & other | $10.4M | −$9.2M | $19.6M | — |
| Cash used in operations | $9.4M | $14.8M | −$5.4M | -36% |
| Net loss absorbed | $22.9M | $8.1M | $14.8M | +184% |
Questions
How much did Aquestive Therapeutics's revenue grow quarter over quarter in Q2 2026?
Aquestive Therapeutics's revenue fell $627K (-4%) from $14.4M in Q1 2026 to $13.8M in Q2 2026.
What drove Aquestive Therapeutics's revenue change in Q2 2026?
License and royalty revenue (a) −$4.1M (-75%); Manufacture and supply revenue +$3.1M (+35%); Co-development and research fees +$324K (+126%).